Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant carboplatin + paclitaxel + pembrolizumab in primary stage IV serous ovarian cancer
2016-004700-56Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in High-Grade Serous Ovarian Cancer (HGSOC) and Fallopian tube high-grade serous carcinoma (HGSC), sponsored by Netherlands Cancer Institute. Primary endpoint: Tumor-specific T cell response in peripheral blood. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)Fallopian tube high-grade serous carcinoma (HGSC)
Beyond the preview
Go deeper on 2016-004700-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004700-56.